home / stock / osmt / osmt news


OSMT News and Press, Osmotica Pharmaceuticals plc From 05/04/23

Stock Information

Company Name: Osmotica Pharmaceuticals plc
Stock Symbol: OSMT
Market: NASDAQ

Menu

OSMT OSMT Quote OSMT Short OSMT News OSMT Articles OSMT Message Board
Get OSMT Alerts

News, Short Squeeze, Breakout and More Instantly...

OSMT - RVL Pharmaceuticals plc to Discuss First Quarter 2023 Financial Results and Provide Commercial Update

BRIDGEWATER, N.J., May 04, 2023 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL” or the “Company”), a specialty pharmaceutical company focused on the commercialization of UPNEEQ ® (oxymetazoline hydrochloride ophthalmic solution), 0.1%, today ...

OSMT - RVL Pharmaceuticals Announces that Upneeq® Wins "Best Eye Drop for Drooping Lids" NewBeauty in 13th Annual Beauty Awards

BRIDGEWATER, N.J., April 03, 2023 (GLOBE NEWSWIRE) --  RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL” or the “Company”) announced today that its prescription eye drop Upneeq® (oxymetazoline hydrochloride ophthalmic solution), 0.1% has been selected the winner ...

OSMT - RVL Pharmaceuticals plc Reports Fourth Quarter and Full Year 2022 Financial Results; Provides Commercial Update

-- RVLP records exceptional year-over-year growth with UPNEEQ ® launch into the medical aesthetics market -- -- Full year 2022 total revenues of $49.7 million, an increase of $32.2 million, or 184%, over 2021 -- -- Full year 2022 UPNEEQ net product sales of $34.2 mill...

OSMT - RVL Pharmaceuticals plc to Discuss Fourth Quarter and Full Year 2022 Financial Results and Provide Commercial Update

BRIDGEWATER, N.J., March 15, 2023 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL” or the “Company”), a specialty pharmaceutical company focused on the commercialization of UPNEEQ ® (oxymetazoline hydrochloride ophthalmic solution), 0.1%, toda...

OSMT - RVL Pharmaceuticals plc Announces Preliminary Fourth Quarter Sequential Growth of 21% and Full Year 2022 UPNEEQ® Net Product Sales

-- Expects fourth quarter 2022 preliminary UPNEEQ net product sales of approximately $12.1 million, representing an increase of 21% over the third quarter 2022, and approximately $36.5 million for full year 2022 -- -- Approximately 4,300 cumulative unique medical aesthetics practices had plac...

OSMT - UPDATE - Osmotica Pharmaceuticals plc Announces Corporate Name Change to RVL Pharmaceuticals plc, New Ticker Symbol "RVLP," Plans to Launch UPNEEQ® into the Medical Aesthetics Market, and Provides Fourth Quarter 2022 Net Sales Guidance

-- Fourth Quarter 2021 net sales for UPNEEQ grew by approximately 41% to $3.1 million compared to the third quarter 2021 -- -- Fourth Quarter 2022 net sales for UPNEEQ targeted to range from $20-$25 million -- -- Full national launch into medical aesthetics expected to commence in...

OSMT - Osmotica Pharmaceuticals plc Announces Corporate Name Change to RVL Pharmaceuticals plc, New Ticker Symbol "RVLP," Plans to Launch UPNEEQ® into the Medical Aesthetics Market, and Provides Fourth Quarter 2022 Net Sales Guidance

-- Fourth Quarter 2021 net sales for UPNEEQ grew by approximately 41% to $3.1 million compared to the third quarter 2021 -- -- Fourth Quarter 2022 net sales for UPNEEQ targeted to range from $20-$25 million -- -- Full national launch into medical aesthetics expected to commence in...

OSMT - RVL Pharmaceuticals to Host UPNEEQ® Overview and Business Update Webcast on January 19, 2022

-- Topics include corporate name change, launch plans into the medical aesthetics market and general business updates -- -- Featured speakers include Dr. Jackie Yee and Dr. Justin Harper -- Bridgewater, N.J., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (NASDAQ: OS...

OSMT - Osmotica Pharmaceuticals plc to Host UPNEEQ® Overview and Business Update Call on January 19, 2022

BRIDGEWATER, N.J., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a specialty pharmaceutical company, announced today that Brian Markison, Chief Executive Officer, James “JD” Schaub, Chie...

OSMT - Osmotica Pharmaceuticals plc to Present at H.C. Wainwright Bioconnect Conference

BRIDGEWATER, N.J., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a specialty pharmaceutical company, announced today that Brian Markison, Chief Executive Officer, James “JD” Schaub, Chie...

Previous 10 Next 10